Kantar Health Blog

  • Building a community one device at a time

    by Brian Mondry | Mar 17, 2015
    Brian Mondry
    We have already seen connectivity in action in the general health and wellness space with Nike, Fitbit and MyFitnessPal providing community extensions for their devices and mobile apps. But the chronic disease space is where the biggest impact will be realized.
    Continue Reading > | Go comment! | Share
  • Brian Mondry
    It seems like the forces are aligned to create a perfect storm that will result in a quantified self world where we are all wiser about the internal workings of our body and all the healthier for it! But wait…
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GU --- Surgical resection is the primary treatment for patients with early-stage renal cell carcinoma (RCC) and can potentially be curative in up to 70% of cases. In many solid tumors, patients at high risk of recurrence are often treated with adjuvant (postsurgical) systemic therapy, with the idea being to eradicate any microscopic residual disease and thus decrease the likelihood of developing a local or metastatic recurrence.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GI --- Patients with metastatic colorectal cancer (mCRC) are typically treated at some point with at least one angiogenesis inhibitor. According to Kantar Health’s CancerMPact® Treatment Architecture U.S. data, Avastin® (bevacizumab, Genentech/Roche) is offered to approximately one-half of KRAS wild-type chemotherapy-naïve patients and three-quarters of KRAS mutated chemotherapy-naïve patients in the first-line setting. In the second- or third-line setting, patients might be treated with Avastin, Zaltrap® (ziv-aflibercept, Sanofi) or Stivarga® (regorafenib, Bayer/Onyx).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GI --- Designated as a “breakthrough therapy” by the FDA for both advanced and unresectable malignant melanoma and advanced non-small cell lung cancer (NSCLC), and approved by the U.S. Food and Drug Administration (FDA) in September 2014 for advanced pretreated metastatic melanoma, the immune checkpoint inhibitor Keytruda® (pembrolizumab, Merck) has also shown promise for several other indications including (but not limited to) head and neck cancer, Hodgkin’s lymphoma and triple-negative breast cancer (TNBC).
    Continue Reading > | Go comment! | Share